Claude Preudhomme

List of Publications by Year in Descending Order

430 papers	20,246 citations	75 h-index	131 g-index
460 ext. papers	23,067 ext. citations	5.4 avg, IF	5.88 L-index

#	Paper	IF	Citations
430	Prognostic Significance of DDX41 Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study. *Blood*, **2021**, 138, 612-612	2.2	0
429	Germline pathogenic variants in transcription factors predisposing to pediatric acute myeloid leukemia: results from the French ELAM02 trial. *Haematologica*, **2021**, 106, 908-912	6.6	2
428	Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. *Haematologica*, **2021**, 106, 3056-3066	6.6	8
427	Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use. *Haematologica*, **2021**, 106, 1767-1769	6.6	2
426	Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML. *Blood Advances*, **2021**, 5, 5258-5268	7.8	1
425	Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a two center experience. *Blood Advances*, **2021**,	7.8	10
424	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. *Nature Communications*, **2021**, 12, 6233	17.4	2
423	2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. *Blood*, **2021**,	2.2	33
422	Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. *Blood Advances*, **2021**, 5, 1540-1551	7.8	10
421	Hereditary Predisposition to Acute Myeloid Leukemia in Older Adults. *HemaSphere*, **2021**, 5, e552	0.3	0
420	The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively. *Cancers*, **2021**, 13,	6.6	3
419	Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications. *Expert Opinion on Therapeutic Targets*, **2021**, 25, 299-309	6.4	1
418	Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. *Blood*, **2021**, 138, 507-519	2.2	7
417	A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis. *Leukemia*, **2021**, 35, 724-736	10.7	3
416	Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study. *Leukemia*, **2021**, 35, 893-896	10.7	1
415	Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia. *Blood*, **2021**, 137, 1424-1428	2.2	11
414	Effects of azacitidine in 93 patients with mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study. *Leukemia and Lymphoma*, **2021**, 62, 438-445	1.9	3

413	A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. *Blood*, **2021**, 137, 524-532	2.2	7
412	Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. *Leukemia*, **2021**, 35, 2332-2345	10.7	0
411	Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. *Leukemia*, **2021**, 35, 2720-2724	10.7	9
410	Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. *Blood*, **2021**, 137, 2827-2837	2.2	7
409	Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. *Blood Advances*, **2020**, 4, 1942-1949	7.8	14
408	Cytogenetically masked fusion and concomitant deletion in a case of acute myeloid leukemia with a complex karyotype. *Leukemia and Lymphoma*, **2020**, 61, 1772-1774	1.9	1
407	The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. *Nature Communications*, **2020**, 11, 1044	17.4	31
406	Baseline dysmegakaryopoiesis in inherited thrombocytopenia/platelet disorder with predisposition to haematological malignancies. *British Journal of Haematology*, **2020**, 189, e119-e122	4.5	5
405	Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow. *Cell Reports*, **2020**, 30, 739-754.e4	10.6	11
404	Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia. *Leukemia*, **2020**, 34, 2230-2233	10.7	1
403	Optical Mapping, a Promising Alternative to Gold Standard Cytogenetic Approaches in Acute Lymphoblastic Leukemias: A Blind Comparison on 10 Patients. *Blood*, **2020**, 136, 39-40	2.2	
402	Impact and Dynamics of TP53 Mutated Clones in Shwachman Diamond Syndrome in a Series of 80 Patients. *Blood*, **2020**, 136, 22-23	2.2	
401	MDS/CMML with TET2 or IDH mutation Are Associated with Systemic Inflammatory and Autoimmune Diseases (SIAD) and T Cell Dysregulation. *Blood*, **2020**, 136, 31-32	2.2	2
400	Familial myeloid malignancies with germline TET2 mutation. *Leukemia*, **2020**, 34, 1450-1453	10.7	20
399	Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients. *American Journal of Hematology*, **2020**, 95, 1314-1323	7.1	15
398	Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19. *Cancers*, **2020**, 12,	6.6	6
397	Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	8
396	Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature. *Blood Advances*, **2020**, 4, 5322-5335	7.8	1

395	Shared clonal IGH rearrangement in BCP-ALL occurring after CLL: pitfalls and implications for MRD monitoring. *British Journal of Haematology*, **2020**, 191, 506-509	4.5	
394	Immature platelet fraction (IPF): A reliable tool to predict peripheral thrombocytopenia. *Current Research in Translational Medicine*, **2020**, 68, 37-42	3.7	7
393	Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. *Blood*, **2020**, 135, 542-546	2.2	28
392	Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study. *Cancers*, **2019**, 11,	6.6	14
391	Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia. *Leukemia*, **2019**, 33, 1814-1816	10.7	7
390	A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. *Haematologica*, **2019**, 104, 1565-1571	6.6	26
389	CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells. *Cancer Medicine*, **2019**, 8, 1279-1288	4.8	16
388	Gemtuzumab ozogamicin for acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. *Haematologica*, **2019**, 104, 113-119	6.6	132
387	The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. *Leukemia*, **2019**, 33, 348-357	10.7	22
386	Chromosomal Abnormalities and Prognosis in -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. *Journal of Clinical Oncology*, **2019**, 37, 2632-2642	2.2	40
385	The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. *Blood*, **2019**, 134, 877-877	2.2	1
384	Clinical Spectrum, Long-Term Outcomes and Predictors of Relapse after Imatinib Discontinuation in FIP1L1-Pdgfra-Associated Chronic Eosinophilic Leukemia: Data from 150 Patients. *Blood*, **2019**, 134, 840-840	2.2	
383	Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype. *Cancers*, **2019**, 12,	6.6	3
382	Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia. *Blood*, **2019**, 134, 2414-2416	2.2	10
381	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. *Blood Advances*, **2019**, 3, 4238-4251	7.8	27
380	Germline Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AML. *HemaSphere*, **2019**, 3, e203	0.3	5
379	Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With Fusion. *HemaSphere*, **2019**, 3, e193	0.3	2
378	Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia. *Haematologica*, **2019**, 104, 1150-1155	6.6	6

377	Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in -rearranged acute lymphoblastic leukemia: a case report and review of the literature. *Leukemia and Lymphoma*, **2019**, 60, 1827-1830	1.9	6
376	Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts-de-France AML observatory. *American Journal of Hematology*, **2019**, 94, E24-E27	7.1	5
375	Clinical relevance of mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group. *Haematologica*, **2018**, 103, 822-829	6.6	24
374	Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. *Leukemia*, **2018**, 32, 2008-2081	10.7	10
373	Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia. *Leukemia*, **2018**, 32, 1856-1860	10.7	4
372	Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up. *Journal of Visualized Experiments*, **2018**,	1.6	3
371	Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study. *European Journal of Human Genetics*, **2018**, 26, 314-323	5.3	39
370	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. *Blood*, **2018**, 131, 1275-1291	2.2	528
369	Down syndrome-like acute megakaryoblastic leukemia in a patient with Cornelia de Lange syndrome. *Haematologica*, **2018**, 103, e274-e276	6.6	7
368	Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group. *HemaSphere*, **2018**, 2, e31	0.3	21
367	Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. *Blood*, **2018**, 132, 187-196	2.2	36
366	Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. *Blood*, **2018**, 131, 289-300	2.2	63
365	Detection of a new heterozygous germline ETV6 mutation in a case with hyperdiploid acute lymphoblastic leukemia. *European Journal of Haematology*, **2018**, 100, 104-107	3.8	11
364	Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A. *Leukemia Research*, **2018**, 71, 67-74	2.7	3
363	mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents. *Haematologica*, **2018**, 103, e455-e457	6.6	15
362	Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. *Haematologica*, **2018**, 103, 1278-1287	6.6	74
361	Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. *EBioMedicine*, **2018**, 31, 174-181	8.8	49
360	Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. *Leukemia*, **2018**, 32, 2066-2069	10.7	3

359	A novel type of mutation characterized by multiple internal tandem repeats in a case of cytogenetically normal acute myeloid leukemia. *Haematologica*, **2018**, 103, e575-e577	6.6	7
358	Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial. *Blood*, **2018**, 132, 993-993	2.2	2
357	A Novel Predictor of Response to Gemtuzumab Ozogamicin Therapy in AML Provides Strategies for Sensitization of Leukemia Stem Cells in Individual Patients. *Blood*, **2018**, 132, 2765-2765	2.2	2
356	Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms. *Blood*, **2018**, 132, 2806-2806	2.2	1
355	A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML). *Blood*, **2018**, 132, 4007-4007	2.2	1
354	SNP-array lesions in core binding factor acute myeloid leukemia. *Oncotarget*, **2018**, 9, 6478-6489	3.3	14
353	Cytom□rie en flux **2018**, 27-39		
352	Maladie r□siduelle mol□culaire **2018**, 301-306		
351	Exploration des prolif□rations lymphoïdes **2018**, 291-299		
350	Stemness Signature in AML: GEP with 17 Genes Score Versus Leukemic Stem Cell (LSC) Quantification By Multiparameter Flow Cytometry (MFC). *Blood*, **2018**, 132, 4009-4009	2.2	
349	Chemotherapy Treatment Doesn't Beneficiate to a Group of Elderly AML Patients with Absence of Complex Karyotype and Circulating Blasts. *Blood*, **2018**, 132, 2679-2679	2.2	
348	Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia. *Hematological Oncology*, **2018**, 36, 422-428	1.3	13
347	Definition of a minimal genes set for mature lymphoid blood diseases. *Hematologie*, **2018**, 24, 27-59	0	4
346	Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia. *Leukemia*, **2018**, 32, 1878-1882	10.7	4
345	Absence of CALR mutations in JAK2-negative polycythemia. *Haematologica*, **2017**, 102, e15-e16	6.6	9
344	Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. *Bone Marrow Transplantation*, **2017**, 52, 539-543	4.4	17
343	Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. *Journal of Clinical Oncology*, **2017**, 35, 1223-1230	2.2	27
342	TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML. *Leukemia Research*, **2017**, 56, 21-28	2.7	3

341	Familial CEBPA-mutated acute myeloid leukemia. *Seminars in Hematology*, **2017**, 54, 87-93	4	35
340	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. *Nature Communications*, **2017**, 8, 15429	17.4	38
339	Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. *Journal of Clinical Oncology*, **2017**, 35, 185-193	2.2	167
338	Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. *Clinical Cancer Research*, **2017**, 23, 6325-6335	12.9	37
337	Copy-number analysis identified new prognostic marker in acute myeloid leukemia. *Leukemia*, **2017**, 31, 555-564	10.7	25
336	High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones. *Leukemia Research*, **2017**, 53, 1-7	2.7	13
335	Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial. *Pediatric Hematology and Oncology*, **2017**, 34, 425-427	1.7	9
334	Reactive oxygen species levels control NF-B activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes. *Oncotarget*, **2017**, 8, 105510-105524	3.3	25
333	Role of IRF4 in resistance to immunomodulatory (IMid) compounds in Waldenstrm's macroglobulinemia. *Oncotarget*, **2017**, 8, 112917-112927	3.3	5
332	promotes indolent clinical presentation in Waldenstrm macroglobulinemia. *Oncotarget*, **2017**, 8, 57451-57459	3.3	2
331	Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia. *Leukemia*, **2016**, 30, 999-1002	10.7	63
330	Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21). *Leukemia and Lymphoma*, **2016**, 57, 199-200	1.9	11
329	Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia. *Haematologica*, **2016**, 101, e365-8	6.6	11
328	Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. *Blood*, **2016**, 127, 749-60	2.2	34
327	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. *Nature Communications*, **2016**, 7, 10767	17.4	140
326	Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists. *Expert Review of Hematology*, **2016**, 9, 1189-1202	2.8	16
325	NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors. *Haematologica*, **2016**, 101, e133-4	6.6	25
324	Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders. *Orphanet Journal of Rare Diseases*, **2016**, 11, 49	4.2	59

323	Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. *Haematologica*, **2016**, 101, 328-35	6.6	73
322	Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. *Lancet Haematology,the*, **2016**, 3, e186-95	14.6	276
321	Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine. *Leukemia*, **2016**, 30, 1416-8	10.7	12
320	Genomic Landscape of CXCR4 Mutations in Waldenstrm Macroglobulinemia. *Clinical Cancer Research*, **2016**, 22, 1480-8	12.9	68
319	Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. *Leukemia*, **2016**, 30, 897-905	10.7	84
318	Oncogenetic Risk Classification Based on NOTCH1/FBXW7/RAS/PTEN Mutation Profiles Improves Outcome Prediction in Pediatric T-Cell Acute Lymphoblastic Leukemia, Treated According the Fralle 2000 T Guidelines. *Blood*, **2016**, 128, 1083-1083	2.2	2
317	De Novo and Secondary Acute Myeloid Leukemia, Real World Data on Outcomes from the French Nord-Pas-De-Calais Picardie Acute Myeloid Leukemia Observatory. *Blood*, **2016**, 128, 4013-4013	2.2	4
316	TP53 Mutation in Waldenstrom Macroglobulinemia. *Blood*, **2016**, 128, 4092-4092	2.2	1
315	Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia. *Oncotarget*, **2016**, 7, 62377-62385	5.9	20
314	Age and Gemtuzumab Ozogamicin Influence the Prognostic Impact of TET2 Expression and Splicing in Intensively Treated Patients with Acute Myeloid Leukemia. *Blood*, **2016**, 128, 3952-3952	2.2	
313	Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases. *Blood*, **2016**, 128, 2861-2861	2.2	
312	Genomic Landscape and Prognosis in Pediatric Acute Myeloid Leukemia: A Study on the French ELAM02 Trial. *Blood*, **2016**, 128, 1676-1676	2.2	
311	Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). *Oncotarget*, **2016**, 7, 2889-909	3.3	16
310	Multi-loci diagnosis of acute lymphoblastic leukaemia with high-throughput sequencing and bioinformatics analysis. *British Journal of Haematology*, **2016**, 173, 413-20	4.5	14
309	Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript. *European Journal of Haematology*, **2016**, 97, 399-402	3.8	7
308	LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis. *Blood*, **2016**, 128, 2694-2707	2.2	29
307	A 17-gene stemness score for rapid determination of risk in acute leukaemia. *Nature*, **2016**, 540, 433-437	50.4	369
306	Comprehensive mutational profiling of core binding factor acute myeloid leukemia. *Blood*, **2016**, 127, 2451-9	2.2	136

305	The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. *Blood*, **2016**, 127, 2157-60	2.2	46
304	A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. *Haematologica*, **2016**, 101, 918-25	6.6	40
303	Paroxysmal nocturnal hemoglobinuria (PNH) and T cell large granular lymphocyte (LGL) leukemia--an unusual association: another cause of cytopenia in PNH. *Annals of Hematology*, **2015**, 94, 1759-60	3	4
302	Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. *Haematologica*, **2015**, 100, 780-5	6.6	34
301	Restoration of hematopoiesis in a case of myelodysplastic syndrome associated with systemic lupus erythematosus treated with rituximab. *Annals of Hematology*, **2015**, 94, 1247-9	3	9
300	Place de la biologie moléculaire pour le diagnostic et le suivi des leucémies aiguës. *Revue Francophone Des Laboratoires*, **2015**, 2015, 51-64	0	1
299	Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia. *Haematologica*, **2015**, 100, e196-9	6.6	12
298	Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. *Leukemia Research*, **2015**, 39, 1443-7	2.7	8
297	Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion. *Journal of Immunology*, **2015**, 195, 2580-90	5.3	49
296	Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules. *Cancer*, **2015**, 121, 490-7	6.4	8
295	A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. *Leukemia*, **2015**, 29, 369-76	10.7	57
294	Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations. *American Journal of Hematology*, **2015**, 90, E93-4	7.1	10
293	Diagnosis of intrachromosomal amplification of chromosome 21 (iAMP21) by molecular cytogenetics in pediatric acute lymphoblastic leukemia. *Clinical Case Reports (discontinued)*, **2015**, 3, 814-6	0.7	3
292	B7-H3 protein expression in acute myeloid leukemia. *Cancer Medicine*, **2015**, 4, 1879-83	4.8	23
291	Disease evolution and outcomes in familial AML with germline CEBPA mutations. *Blood*, **2015**, 126, 1214-23	22.3	104
290	Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis. *American Journal of Hematology*, **2015**, 90, 737-8	7.1	13
289	Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia. *Oncotarget*, **2015**, 6, 22812-21	3.3	37
288	Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia. *Oncotarget*, **2015**, 6, 36269-77	3.3	23

287	Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma. *British Journal of Haematology*, **2015**, 170, 285-7	4.5	14
286	Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes. *Leukemia Research*, **2015**,	2.7	2
285	Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. *Expert Review of Hematology*, **2015**, 8, 43-56	2.8	21
284	CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. *Haematologica*, **2015**, 100, 1086-95	6.6	24
283	HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML. *Blood*, **2015**, 126, 1307-1307	2.2	7
282	A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM. *Blood*, **2015**, 126, 2872-2872	2.2	1
281	Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation. *Blood*, **2015**, 126, 3833-3833	2.2	1
280	IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. *Oncotarget*, **2015**, 6, 42345-53	3.3	78
279	Correlation Between Bone Marrow Dysplasia and Genomic Profile in De Novo Acute Myeloid Leukemia (AML): A Study By the ALFA Group. *Blood*, **2015**, 126, 2568-2568	2.2	
278	NPM1 Minimal Residual Disease As Prognostic and Predictive Factor in Young Adults with Acute Myeloid Leukemia: a Study By the French ALFA Group. *Blood*, **2015**, 126, 2581-2581	2.2	
277	Liver X Receptor Agonists: A Potential Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm. *Blood*, **2015**, 126, 4933-4933	2.2	
276	Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. *Journal of Clinical Oncology*, **2014**, 32, 297-305	2.2	94
275	Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse. *American Journal of Hematology*, **2014**, 89, 399-403	7.1	20
274	Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. *Blood*, **2014**, 124, 1445-9	2.2	93
273	Fast multiclonal clusterization of V(D)J recombinations from high-throughput sequencing. *BMC Genomics*, **2014**, 15, 409	4.5	51
272	Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib. *Leukemia Research*, **2014**, 38, 662-5	2.7	14
271	Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale. *Clinical Biochemistry*, **2014**, 47, 1333-6	3.5	8
270	Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. *Leukemia Research*, **2014**, 38, 751-5	2.7	112

269	SET-NUP214 is a recurrent lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL. *Blood*, **2014**, 123, 1860-3	2.2	27
268	5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies. *European Journal of Cancer*, **2014**, 50, 196	7.5	12
267	MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. *British Journal of Haematology*, **2014**, 167, 506-13	4.5	49
266	Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA. *American Journal of Hematology*, **2014**, 89, 610-5	7.1	19
265	Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies **2014**,		17
264	Multiclonal Diagnosis and MRD Follow-up in ALL with HTS Coupled with a Bioinformatic Analysis. *Blood*, **2014**, 124, 1083-1083	2.2	1
263	Procoagulant Platelet-Derived Microparticles Are Lower in Calreticulin-Than in-JAK2-Mutated Essential Thrombocythemia. *Blood*, **2014**, 124, 110-110	2.2	1
262	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia. *Blood*, **2014**, 124, 117-117	2.2	24
261	Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group. *Blood*, **2014**, 124, 2327-2327	2.2	1
260	Results of the Evaluation of NGS in AML-Diagnostics (ELAN) Study an Inter-Laboratory Comparison Performed in 10 European Laboratories. *Blood*, **2014**, 124, 2374-2374	2.2	1
259	Final Analysis of the ALFA 0701 Study. *Blood*, **2014**, 124, 376-376	2.2	17
258	Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA). *Blood*, **2014**, 124, 482-482	2.2	1
257	NPM1 Expression Level and a CRBN Polymorphism Are Able to Predict the Rate of Response to Lenalidomide in Non Del(5q) Lower Risk MDS Patients Resistant to Erythropoiesis-Stimulating Agents: The GFM Experience. *Blood*, **2014**, 124, 533-533	2.2	1
256	Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial. *Oncotarget*, **2014**, 5, 916-32	3.3	40
255	Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines. *Oncotarget*, **2014**, 5, 4384-91	3.3	13
254	MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. *Oncotarget*, **2014**, 5, 6280-8	3.3	54
253	Epidemiology of Adults AML in Nord-Pas De Calais and Picardy. *Blood*, **2014**, 124, 2281-2281	2.2	
252	Incidence of Atrx Mutations in Myelodysplastic Syndromes (MDS). *Blood*, **2014**, 124, 4629-4629	2.2	

251	Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics. *Blood*, **2014**, 124, 2324-2324	2.2	
250	Absolute Quantification of EVI1 Overexpression in Acute Myeloid Leukemia By RQ-PCR Analysis : A Study of the ALFA Group. *Blood*, **2014**, 124, 1062-1062	2.2	
249	Detection of TP53 Mutations in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). a Comparison Between a Functional Method (FASAY) and Next Generation Sequencing (NGS). *Blood*, **2014**, 124, 3266-3266	2.2	0
248	Prognostic Analysis of GATA2 Mutations in CEBPA-Mutated Acute Myeloid Leukemia. *Blood*, **2014**, 124, 2360-2360	2.2	
247	TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy. *Blood*, **2014**, 124, 68-68	2.2	
246	Genomic Landscape of Pediatric CBF-AML By SNP-Array Karyotyping and Extensive Mutational Analysis. *Blood*, **2014**, 124, 1007-1007	2.2	
245	Tolerability and efficacy of pegylated interferon-α2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia. *Cancer*, **2013**, 119, 4284-9	6.4	14
244	Quantification of JAK2V617F mutation by next-generation sequencing technology. *American Journal of Hematology*, **2013**, 88, 536-7	7.1	9
243	Clonal architecture of chronic myelomonocytic leukemias. *Blood*, **2013**, 121, 2186-98	2.2	189
242	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. *Blood*, **2013**, 121, 2213-23	2.2	248
241	Prognostic score including gene mutations in chronic myelomonocytic leukemia. *Journal of Clinical Oncology*, **2013**, 31, 2428-36	2.2	373
240	SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. *Leukemia*, **2013**, 27, 1401-3	10.7	88
239	Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. *Journal of Clinical Oncology*, **2013**, 31, 321-7	2.2	55
238	Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia. *American Journal of Hematology*, **2013**, 88, 306-11	7.1	38
237	Outcome of older patients with acute myeloid leukemia in first relapse. *American Journal of Hematology*, **2013**, 88, 758-64	7.1	32
236	Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. *American Journal of Hematology*, **2013**, 88, 948-54	7.1	37
235	MYD88 L265P mutation in Waldenstrom macroglobulinemia. *Blood*, **2013**, 121, 4504-11	2.2	166
234	BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. *Blood*, **2013**, 122, 3169-77	2.2	147

233	Acute myeloid leukemia with translocation t(3;5): new molecular insights. *Haematologica*, **2013**, 98, e52-4	6.6	9
232	The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases. *Medicine (United States)*, **2013**, 92, e1-e9	1.8	62
231	New-generation sequencing (NGS) in hematologic oncology laboratories. *Hematologie*, **2013**, 19, 112-122	0	2
230	Linezolid induces ring sideroblasts. *Haematologica*, **2013**, 98, e138-40	6.6	12
229	Assessment Of Minimal Residual Disease In Acute Myeloblastic Leukemia In Multiparameter Flow Cytometry. *Blood*, **2013**, 122, 2613-2613	2.2	1
228	The B7-H3 Protein In Acute Myeloid Leukemia. *Blood*, **2013**, 122, 2620-2620	2.2	1
227	Prognostic Factors Of Response and Survival To Azacitidine (AZA) +/- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM. *Blood*, **2013**, 122, 658-658	2.2	1
226	The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. *Blood*, **2013**, 122, 743-743	2.2	6
225	High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients. *Oncotarget*, **2013**, 4, 1582-91	3.3	20
224	Minimal Residual Disease Monitoring In t(8;21) Acute Myeloid Leukemia Based On RUNX1-RUNX1T1 Fusion Quantification On Genomic DNA. *Blood*, **2013**, 122, 1353-1353	2.2	
223	Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing. *Blood*, **2013**, 122, 740-740	2.2	
222	Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. *Leukemia Research*, **2012**, 36, 316-23	2.7	47
221	Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. *Lancet, The*, **2012**, 379, 1508-16	40	646
220	Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. *Leukemia Research*, **2012**, 36, 1112-8	2.7	6
219	Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis. *Leukemia Research*, **2012**, 36, 1330-3	2.7	7
218	BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. *Oncotarget*, **2012**, 3, 490-501	3.3	66
217	Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. *Leukemia*, **2012**, 26, 1247-54	10.7	109
216	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. *Blood*, **2012**, 119, 3211-8	2.2	188

215	Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML. *Bone Marrow Transplantation*, **2012**, 47, 1436-41	4.4	9
214	Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. *Haematologica*, **2012**, 97, 890-4	6.6	70
213	GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells. *Oncogene*, **2012**, 31, 1419-30	9.2	32
212	Classification et facteurs pronostiques des leucémies aiguës. *EMC Hématologie*, **2012**, 7, 1-17		2
211	MYD88 L265P Mutation in Waldenstrom's Macroglogulinemia. *Blood*, **2012**, 120, 1307-1307	2.2	2
210	The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories. *Blood*, **2012**, 120, 1399-1399	2.2	6
209	Relationship Between Molecular Responses and Disease Progression in Patients (Pts) Treated First Line with Imatinib (Im) Based Regimens: Impact of Treatment Arm within the French Spirit Trial From the French CML Group (FI LMC). *Blood*, **2012**, 120, 168-168	2.2	4
208	Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine. *Blood*, **2012**, 120, 1706-1706	2.2	2
207	Genome Wide SNP Array (SNPa) Analysis Reveals Clonal Evolution During Clinical Course in Waldenstrom's Macroglobulinemia (WM). *Blood*, **2012**, 120, 297-297	2.2	2
206	Comprehensive Genetic Screening of Chronic Myelomonocytic Leukemias (CMML). *Blood*, **2012**, 120, 3811-3811	2.2	1
205	BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients. *Blood*, **2012**, 120, 701-701	2.2	1
204	BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes. *Blood*, **2012**, 120, 1697-1697	2.2	
203	Incidence and Prognostic Value of TP53 Mutations in Lower Risk MDS with Del 5q.. *Blood*, **2012**, 120, 2809-2809	2.2	
202	B-Cell-Specific Transcription Factor BACH2 Involved in the Clinical Behavior Heterogeneity of Waldenstro m Macroglobulinemia. *Blood*, **2012**, 120, 1288-1288	2.2	
201	DEK and WT1 Affect Alternative Splicing of Genes Involved in Hematopoietic Cell Lineage and Resistance to Chemotherapy in Acute Myeloid Leukemia Cells.. *Blood*, **2012**, 120, 2392-2392	2.2	
200	Two Distinct Mechanisms Contribute to Granulomonocytic Hyperplasia in Chronic Myelomonocytic Leukemias (CMML). *Blood*, **2012**, 120, 309-309	2.2	
199	Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia. *Leukemia*, **2011**, 25, 1661-4	10.7	31
198	Implication of IDH1 and IDH2 gene mutations in acute myeloid leukemia. *Hematologie*, **2011**, 17, 132-144	0	

197	Wilms Tumor 1 (WT1) and acute leukemia. *Hematologie*, **2011**, 17, 40-60	0	
196	Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. *Blood*, **2011**, 117, e161-70	2.2	126
195	Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. *Blood*, **2011**, 117, 3696-7	2.2	32
194	Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study. *Blood*, **2011**, 118, 4331-7	2.2	29
193	Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. *Blood*, **2011**, 118, 1754-62	2.2	42
192	Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. *Blood*, **2011**, 118, 3824-31	2.2	166
191	Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. *Leukemia*, **2011**, 25, 1147-52	10.7	369
190	Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): evolution on hypomethylating agent therapy. *Leukemia Research*, **2011**, 35, e203-5	2.7	4
189	Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias. *Experimental Hematology*, **2011**, 39, 195-202.e2	3.1	29
188	Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia. *Leukemia*, **2011**, 25, 1918-21	10.7	11
187	Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients. *Leukemia Research*, **2011**, 35, 448-58	2.7	14
186	Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50 70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA). *Blood*, **2011**, 118, 6-6	2.2	5
185	Chromosomal minimal critical regions in therapy-related leukemia appear different from those of de novo leukemia by high-resolution aCGH. *PLoS ONE*, **2011**, 6, e16623	3.7	21
184	Older Patients with Acute Myeloid Leukemia (AML) in First Relapse: Impact of Genetics and of Salvage Therapy. A Study of the Acute Leukemia French Association (ALFA). *Blood*, **2011**, 118, 253-253	2.2	0
183	Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial. *Blood*, **2011**, 118, 410-410	2.2	
182	SNP Array Analysis in Acute Myeloid Leukemia Reveals Frequent and Recurrent Acquired Genetic Alterations Linked to Prognosis: a Study of the ALFA Group. *Blood*, **2011**, 118, 2533-2533	2.2	
181	Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. *British Journal of Haematology*, **2010**, 151, 460-8	4.5	56
180	Extensive mutational status of genes and clinical outcome in pediatric acute myeloid leukemia. *Leukemia*, **2010**, 24, 205-9	10.7	7

179	Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies. *Leukemia*, **2010**, 24, 476-80	10.7	17
178	Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience. *Leukemia*, **2010**, 24, 1386-8	10.7	16
177	Recommandations du groupe FI-LMC pour la prise en charge des patients présentant des mutations du domaine tyrosine kinase de BCR-ABL dans les hémopathies malignes à chromosome Philadelphie. *Hematologie*, **2010**, 16, 65-79	0	6
176	Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. *Journal of Clinical Oncology*, **2010**, 28, 808-14	2.2	173
175	NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. *Leukemia*, **2010**, 24, 2023-31	10.7	106
174	Activity of ladanein on leukemia cell lines and its occurrence in Marrubium vulgare. *Planta Medica*, **2010**, 76, 86-7	3.1	27
173	Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. *New England Journal of Medicine*, **2010**, 363, 2511-21	59.2	304
172	Humulane and germacrane sesquiterpenes from Ferula lycia. *Journal of Natural Products*, **2010**, 73, 780-3	4.9	8
171	Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. *Journal of Clinical Oncology*, **2010**, 28, 3717-23	2.2	157
170	C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. *Blood*, **2010**, 116, 5638-49	2.2	104
169	Response: is there really a relationship between Multidrug Resistance Gene (MDR1) polymorphisms and major molecular response to imatinib in chronic myeloid leukemia?. *Blood*, **2010**, 116, 6145-6146	2.2	21
168	Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. *Blood*, **2010**, 116, 1132-5	2.2	105
167	Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. *Cancer*, **2010**, 116, 1725-32	6.4	22
166	Presence of TET2 Mutation Predicts A Higher Response Rate to Azacitidine In MDS and AML Post MDS. *Blood*, **2010**, 116, 439-439	2.2	6
165	Deletion of the Tumor Suppressor Gene NF1 Is Found In 3.5% of 485 De Novo Adult Myeloid Leukemia and Is Correlated with Unfavourable Cytogenetic: On Behalf of the ALFA Group. *Blood*, **2010**, 116, 4171-4171	2.2	
164	A Recurrent Pattern of Acquired Genomic Abnormalities In Myelodysplasia and Leukemia of Fanconi Anemia Includes Cryptic RUNX1/AML1 abnormalities. *Blood*, **2010**, 116, 975-975	2.2	
163	Prognostic Impact of Wilms Tumor 1 Single Nucleotide Polymorphism rs16754 In Older Patients with Acute Myeloid Leukemia. *Blood*, **2010**, 116, 2701-2701	2.2	
162	Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. *Blood*, **2009**, 114, 5271-8	2.2	87

161	Place de la biologie moléculaire dans l'évaluation pronostique des patients atteints de leucémie aiguë myéloïde. *Hematologie*, **2009**, 15, 426-443	0	
160	Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?. *Current Opinion in Hematology*, **2009**, 16, 92-7	3.3	25
159	Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. *Cancer*, **2009**, 115, 3719-27	6.4	64
158	Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. *Leukemia*, **2009**, 23, 804-6	10.7	37
157	The molecular anatomy of the FIP1L1-PDGFRA fusion gene. *Leukemia*, **2009**, 23, 271-8	10.7	16
156	PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. *Leukemia*, **2009**, 23, 1989-98	10.7	81
155	Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. *Journal of Clinical Oncology*, **2009**, 27, 5195-201	2.2	337
154	Slow relapse in acute myeloid leukemia with inv(16) or t(16;16). *Haematologica*, **2009**, 94, 1466-8	6.6	5
153	C/EBPA methylation is common in T-ALL but not in M0 AML. *Blood*, **2009**, 113, 1864-6; author reply 1866	2.2	6
152	The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. *Blood*, **2009**, 113, 5090-3	2.2	75
151	High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. *Blood*, **2009**, 113, 5583-7	2.2	130
150	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). *Blood*, **2009**, 114, 3285-91	2.2	231
149	The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication. *Blood*, **2009**, 114, 4601-2; author reply 4602-3	2.2	15
148	Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML).. *Blood*, **2009**, 114, 163-163	2.2	3
147	Cooperating gene mutations in acute myeloid leukemia: a review of the literature. *Leukemia*, **2008**, 22, 915-31	10.7	271
146	Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML. *Leukemia*, **2008**, 22, 655-7	10.7	11
145	JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. *Leukemia*, **2008**, 22, 1454-5	10.7	41
144	BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. *Leukemia*, **2008**, 22, 791-9	10.7	37

143	Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression?. *Genes Chromosomes and Cancer*, **2008**, 47, 1110-7	5	12
142	RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. *Blood*, **2008**, 111, 3735-41	2.2	59
141	Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia. *Genes Chromosomes and Cancer*, **2008**, 47, 915-8	5	22
140	Activity of elaeochytrin A from Ferula elaeochytris on leukemia cell lines. *Phytochemistry*, **2008**, 69, 2979-83	4	33
139	The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia: Final Report on 3252 Cases from the International MILE Study Group. *Blood*, **2008**, 112, 753-753	2.2	10
138	Kinetic of chronic myeloid leukaemia (CML) prevalence in Northern France since the introduction of imatinib. *Journal of Clinical Oncology*, **2008**, 26, 7088-7088	2.2	11
137	Incidence and Prognostic Impact of SNPs Regulating PU.1 Gene Expression in AML. *Blood*, **2008**, 112, 2949-2949	2.2	
136	Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. *Leukemia*, **2007**, 21, 453-61	10.7	65
135	Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation. *Leukemia*, **2007**, 21, 2376-7	10.7	10
134	The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus. *Leukemia*, **2007**, 21, 2428-32	10.7	23
133	Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. *Haematologica*, **2007**, 92, 1238-41	6.6	50
132	Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. *Blood*, **2007**, 109, 4635-40	2.2	167
131	Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. *Blood*, **2007**, 109, 5129-35	2.2	138
130	Randomized Comparison of Standard Induction with Daunorubicin (DNR) for 3 Days vs Idarubicin (IDA) for 3 or 4 Days in AML pts Aged 50 to 70 and of Maintenance with Interleukin 2. Final Analysis of the ALFA 9801 Study.. *Blood*, **2007**, 110, 162-162	2.2	11
129	PAX5 Mutations Occur Frequently in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Is Significantly Associated with BCR-ABL1 Fusion Gene.. *Blood*, **2007**, 110, 2806-2806	2.2	1
128	Real-Time Quantitative PCR (RQ-PCR) Detection of Minimal Residual Disease (MRD) by Optimized WT1 Assay To Enhance Risk Stratification in Acute Myeloid Leukemia (AML): A European LeukemiaNet Study.. *Blood*, **2007**, 110, 542-542	2.2	3
127	Evaluation of Minimal Residual Disease Based on NPM1 Mutations in AML with Intermediate Risk Cytogenetics: A Prospective Study of 36 Patients.. *Blood*, **2007**, 110, 2847-2847	2.2	
126	Prognostic Value of Minimal Residual Disease by Real-Time Quantitative PCR in AML with CBFB-MYH11 Rearrangement: The French Experience.. *Blood*, **2007**, 110, 3496-3496	2.2	

125	High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. *Journal of Clinical Oncology*, **2006**, 24, 1507-15	2.2	141
124	AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. *Blood*, **2006**, 107, 1166-73	2.2	192
123	Cooperation of activating Ras/rtk signal transduction pathway mutations and inactivating myeloid differentiation gene mutations in M0 AML: a study of 45 patients. *Leukemia*, **2006**, 20, 433-6	10.7	16
122	Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). *Leukemia*, **2006**, 20, 965-70	10.7	287
121	Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). *Leukemia*, **2006**, 20, 1061-6	10.7	185
120	High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. *Leukemia*, **2006**, 20, 2067-70	10.7	56
119	Prospective multicentric molecular study for poor prognosis fusion transcripts at diagnosis in adult B-lineage ALL patients: the LALA 94 experience. *Leukemia*, **2006**, 20, 2178-81	10.7	7
118	Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. *Leukemia*, **2006**, 20, 2155-61	10.7	52
117	Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. *Blood*, **2005**, 106, 3618-20	2.2	191
116	Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia. *Bone Marrow Transplantation*, **2005**, 35, 767-73	4.4	18
115	CEBPA point mutations in hematological malignancies. *Leukemia*, **2005**, 19, 329-34	10.7	134
114	Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). *Leukemia*, **2005**, 19, 367-72	10.7	101
113	Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. *Leukemia*, **2005**, 19, 792-8	10.7	87
112	Mutation in RAP1 is a rare event in myelodysplastic syndromes. *Leukemia*, **2005**, 19, 1678-80	10.7	13
111	Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML. *Leukemia*, **2005**, 19, 1991-2	10.7	11
110	IgH/TCR rearrangements are common in MLL translocated adult AML and suggest an early T/myeloid or B/myeloid maturation arrest, which correlates with the MLL partner. *Leukemia*, **2005**, 19, 2337-8	10.7	14
109	Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro. *Oncogene*, **2005**, 24, 2441-8	9.2	63
108	Role of multiplex FISH in identifying chromosome involvement in myelodysplastic syndromes and acute myeloid leukemias with complex karyotypes: a report on 28 cases. *Cancer Genetics and Cytogenetics*, **2005**, 157, 118-26		28

107	Therapy-related acute lymphoblastic leukemia with MLL rearrangement following treatment of Burkitt's leukemia. *Leukemia and Lymphoma*, **2005**, 46, 925-7	1.9	3
106	Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft. *Leukemia*, **2004**, 18, 354-5	10.7	16
105	A case of refractory anemia with 17p- syndrome following azathioprine treatment for heart transplantation. *Leukemia*, **2004**, 18, 878	10.7	6
104	Chromosomal insertion involving MLL in childhood acute myeloblastic leukemia (M4). *Cancer Genetics and Cytogenetics*, **2004**, 150, 153-5		3
103	Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. *Blood*, **2004**, 103, 442-50	2.2	123
102	Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. *Blood*, **2004**, 104, 2467-74	2.2	71
101	European Multicenter Experience on Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement treated with Imatinib.. *Blood*, **2004**, 104, 1507-1507	2.2	1
100	Molecular Heterogeneity of the FIP1L1-PDGFRA Fusion Gene in Chronic Eosinophilic Leukemia (CEL) and Systemic Mastocytosis with Eosinophilia (SME): A Study of 43 Cases.. *Blood*, **2004**, 104, 2428-2428	2.2	2
99	Molecular Characterization of the Idiopathic Hypereosinophilic Syndrome (HES) in 35 French Patients with Normal Conventional Cytogenetics.. *Blood*, **2004**, 104, 2442-2442	2.2	2
98	Incidence and Prognosis of RTKs and RAS Mutations in CBF AML. A Retrospective Study of French Adult ALFA and Pediatric LAME Trials.. *Blood*, **2004**, 104, 2022-2022	2.2	1
97	A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. *New England Journal of Medicine*, **2003**, 348, 2265-6	59.2	76
96	M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Fran□is d'H□matologie Cellulaire (GFHC) and the Groupe Fran□is de Cytog□□ique H□matologique (GFCH). *Blood*, **2003**, 101, 1277-83	2.2	65
95	New mechanisms of AML1 gene alteration in hematological malignancies. *Leukemia*, **2003**, 17, 9-16	10.7	112
94	Absence of somatic mutations within the Runt domain of AML2/RUNX3 in acute myeloid leukaemia. *Leukemia*, **2003**, 17, 1677-8	10.7	11
93	Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow transplantation for T-ALL. *Leukemia*, **2003**, 17, 2056-7	10.7	26
92	Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. *Seminars in Hematology*, **2003**, 40, 80-2	4	67
91	Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. *Seminars in Hematology*, **2003**, 40, 80-82	4	
90	The Arg200Trp Mutation in the Human Tissue Factor Gene. *Thrombosis and Haemostasis*, **2002**, 87, 540-541	7	2

89	TPA stimulation culture for improved detection of t(11;14)(q13;q32) in mantle cell lymphoma. *Annales De G□ n□ tique*, **2002**, 45, 165-8		2
88	Acquired trisomy 21 and distinct clonal evolution in acute megakaryoblastic leukaemia in young monozygotic twins. *British Journal of Haematology*, **2002**, 118, 1082-6	4.5	13
87	Biologie mol□ulaire et leuc□mies aigu□s. *Revue Francaise Des Laboratoires*, **2002**, 2002, 41-46		
86	Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. *Leukemia*, **2002**, 16, 1699-704	10.7	101
85	Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. *Blood*, **2002**, 100, 1014-8	2.2	448
84	Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). *Blood*, **2002**, 100, 2717-23	2.2	436
83	Amplification of AML1 gene is present in childhood acute lymphoblastic leukemia but not in adult, and is not associated with AML1 gene mutation. *Leukemia*, **2002**, 16, 1131-4	10.7	38
82	Acute myeloblastic leukemia (AML) with inv (16)(p13;q22) and the rare I type CBFbeta-MYH11 transcript: report of two new cases. *Leukemia*, **2002**, 16, 150-1	10.7	12
81	Unlike AML1, CBFbeta gene is not deregulated by point mutations in acute myeloid leukemia and in myelodysplastic syndromes. *Blood*, **2002**, 99, 3848-50	2.2	10
80	Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)?. *Blood*, **2002**, 100, 4680-1	2.2	35
79	Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France. *British Journal of Haematology*, **2001**, 112, 927-35	4.5	61
78	Prognostic significance of p16INK4a immunocytochemistry in adult ALL with standard risk karyotype. *Leukemia*, **2001**, 15, 1054-9	10.7	7
77	MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). *Genes Chromosomes and Cancer*, **2000**, 28, 138-44	5	138
76	Expression of the multidrug resistance-associated protein in myelodysplastic syndromes. *British Journal of Haematology*, **2000**, 110, 591-8	4.5	18
75	Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease. *Gene Therapy*, **2000**, 7, 1312-6	4	39
74	Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma. *Oncogene*, **2000**, 19, 2023-32	9.2	102
73	High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. *Blood*, **2000**, 96, 2862-2869	2.2	220
72	Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients. *Journal of Clinical Oncology*, **2000**, 18, 788-94	2.2	65

71	High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. *Blood*, **2000**, 96, 2862-2869	2.2	13
70	Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. *British Journal of Haematology*, **2000**, 111, 801-6	4.5	104
69	A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. *Blood*, **1999**, 94, 1192-1200	2.2	606
68	Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. *Leukemia*, **1999**, 13, 250-7	10.7	85
67	Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using an in situ RT-PCR assay. *Leukemia*, **1999**, 13, 818-23	10.7	13
66	Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay. *Leukemia*, **1999**, 13, 957-64	10.7	94
65	A new murine aggressive leukemic model. *Leukemia Research*, **1999**, 23, 415-6	2.7	17
64	A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. *Blood*, **1999**, 94, 1192-1200	2.2	8
63	p190 bcr-abl rearrangement: a secondary cytogenetic event in some chronic myeloid disorders?. *Haematologica*, **1999**, 84, 1075-80	6.6	14
62	Myelodysplasia during the course of myeloma. Restriction of 17p deletion and p53 overexpression to myeloid cells. *Leukemia*, **1998**, 12, 238-41	10.7	4
61	Very low incidence of p53 antibodies in adult non-Hodgkin's lymphoma and multiple myeloma. *British Journal of Haematology*, **1998**, 100, 184-6	4.5	3
60	Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes. *Leukemia and Lymphoma*, **1998**, 29, 547-51	1.9	16
59	17p Deletion in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Analysis of Breakpoints and Deleted Segments by Fluorescence In Situ. *Blood*, **1998**, 91, 1008-1015	2.2	108
58	Acute Myeloid Leukemia and Myelodysplastic Syndromes Following Essential Thrombocythemia Treated With Hydroxyurea: High Proportion of Cases With 17p Deletion. *Blood*, **1998**, 91, 616-622	2.2	331
57	Methylation of the p15INK4b Gene in Myelodysplastic Syndromes Is Frequent and Acquired During Disease Progression. *Blood*, **1998**, 91, 2985-2990	2.2	302
56	Homozygous G20210A Transition in the Prothrombin Gene Associated with Severe Venous Thrombotic Disease: Two Cases in a French Family. *Thrombosis and Haemostasis*, **1998**, 80, 1027-1028	7	24
55	17p Deletion in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Analysis of Breakpoints and Deleted Segments by Fluorescence In Situ. *Blood*, **1998**, 91, 1008-1015	2.2	4
54	Genomic structure and assignment of the RhoH/TTF small GTPase gene (ARHH) to 4p13 by in situ hybridization. *Genomics*, **1997**, 43, 89-94	4.3	34

53	Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL). *Leukemia*, **1997**, 11, 294-8	10.7	73
52	Glutathione S transferase theta 1 gene defects in myelodysplastic syndromes and their correlation with karyotype and exposure to potential carcinogens. *Leukemia*, **1997**, 11, 1580-2	10.7	36
51	ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia. *Leukemia*, **1997**, 11, 1459-64	10.7	94
50	The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies. *British Journal of Haematology*, **1997**, 98, 502-11	4.5	96
49	Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders. *British Journal of Haematology*, **1997**, 98, 983-91	4.5	61
48	p16ink4a gene and hematological malignancies. *Leukemia and Lymphoma*, **1996**, 22, 11-24	1.9	25
47	Identification of a YAC spanning the translocation breakpoint t(8;22) associated with acute monocytic leukemia. *Genes Chromosomes and Cancer*, **1996**, 15, 191-4	5	19
46	Biologie mol□ulaire des syndromes myl□odysplasiques. *Revue Francaise Des Laboratoires*, **1996**, 1996, 33-37		
45	Transfer of p16inka/CDKN2 gene in leukaemic cell lines inhibits cell proliferation. *British Journal of Haematology*, **1996**, 95, 291-8	4.5	21
44	Is apoptosis a massive process in myelodysplastic syndromes?. *British Journal of Haematology*, **1996**, 95, 368-71	4.5	72
43	Analysis of p16 gene deletion and point mutation in breast carcinoma. *British Journal of Cancer*, **1995**, 72, 351-3	8.7	36
42	Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases. *Journal of Clinical Oncology*, **1995**, 13, 812-20	2.2	71
41	T-cell acute lymphoblastic leukemia occurring in the course of B cell chronic lymphocytic leukemia: a case report. *Leukemia and Lymphoma*, **1995**, 18, 361-4	1.9	6
40	Good predictive value of combined cytogenetic and molecular follow up in chronic myelogenous leukemia after non T-cell depleted allogeneic bone marrow transplantation: a report on 38 consecutive cases. *Leukemia and Lymphoma*, **1995**, 18, 265-71	1.9	12
39	The retinoblastoma gene (RB-1) status in multiple myeloma: a report on 35 cases. *Leukemia and Lymphoma*, **1995**, 18, 497-503	1.9	28
38	Combined immunophenotyping and in situ hybridization (FICTION): a rapid method to study cell lineage involvement in myelodysplastic syndromes. *British Journal of Haematology*, **1995**, 90, 701-6	4.5	36
37	bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis. *Leukemia*, **1995**, 9, 726-30	10.7	24
36	p16 gene homozygous deletions in acute lymphoblastic leukemia. *Blood*, **1995**, 85, 657-63	2.2	12

35	Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations. *Leukemia*, **1995**, 9, 370-81	10.7	141
34	p16 gene homozygous deletions in acute lymphoblastic leukemia. *Blood*, **1995**, 85, 657-663	2.2	95
33	p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. *Blood*, **1994**, 84, 3148-3157	2.2	496
32	Significance of circulating plasma cells in multiple myeloma. *Leukemia and Lymphoma*, **1994**, 14, 491-6	1.9	5
31	Immunoglobulin and T-cell receptor delta gene rearrangements are rarely found in myelodysplastic syndromes in chronic phase. *Leukemia Research*, **1994**, 18, 365-71	2.7	9
30	Inactivation of the retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes. *British Journal of Haematology*, **1994**, 87, 61-7	4.5	32
29	Over-expression of the MDM2 gene is found in some cases of haematological malignancies. *British Journal of Haematology*, **1994**, 88, 415-8	4.5	52
28	MDM2 gene amplification in human breast cancer. *European Journal of Cancer*, **1994**, 30A, 982-4	7.5	47
27	Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. *Leukemia*, **1994**, 8, 998-1004	10.7	19
26	Inactivation of the p53 gene in leukemias and myelodysplastic syndrome (MDS) with 17p monosomy. *Leukemia*, **1994**, 8, 2241-2	10.7	8
25	p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. *Blood*, **1994**, 84, 3148-57	2.2	134
24	Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. *Leukemia*, **1994**, 8, 1342-9	10.7	54
23	Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia. *Leukemia*, **1994**, 8, 1589-91	10.7	21
22	Fluorescence in situ hybridization improves the detection of monosomy 7 in myelodysplastic syndromes. *Leukemia*, **1994**, 8, 1012-8	10.7	33
21	p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. *Blood*, **1994**, 84, 3148-3157	2.2	21
20	Presence of inv (16) May Be One of the Only Favorable Prognostic Factors in AML: A Report on 16 Cases. *Hamatologie Und Bluttransfusion*, **1994**, 602-605		
19	Absence of germline mutations of exons 5 to 8 of the P53 gene in 26 breast cancer families from the north of France. *European Journal of Cancer*, **1993**, 29A, 1476-8	7.5	8
18	Improved cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in multiple myeloma: a report on 46 patients. *British Journal of Haematology*, **1993**, 84, 743-5	4.5	37

17	De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features?. *Leukemia Research*, **1993**, 17, 921-6	2.7	50
16	Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. *Cancer Research*, **1993**, 53, 5872-6	10.1	132
15	Philadelphia negative, BCR-ABL positive adult acute lymphoblastic leukemia (ALL) in 2 of 39 patients with combined cytogenetic and molecular analysis. *Leukemia*, **1993**, 7, 1054-7	10.7	5
14	Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes. *Leukemia*, **1993**, 7, 1291-3	10.7	19
13	Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. *Leukemia*, **1993**, 7, 1315-23	10.7	230
12	The role of intensive chemotherapy in myelodysplastic syndromes. *Leukemia and Lymphoma*, **1992**, 8, 43-9	1.9	14
11	Acute monocytic leukemia with (8;22)(p11;q13) translocation. Involvement of 8p11 as in classical t(8;16)(p11;p13). *Cancer Genetics and Cytogenetics*, **1992**, 60, 180-2		38
10	Cytogenetic and molecular remission in a case of acute myeloid leukaemia(AML) with inversion of chromosome 16 (Inv(16)) and Philadelphia chromosome (Ph). *British Journal of Haematology*, **1992**, 82, 623-6	4.5	23
9	Rare occurrence of P53 gene mutations in multiple myeloma. *British Journal of Haematology*, **1992**, 81, 440-3	4.5	66
8	Mutations of the P53 gene in acute myeloid leukaemia. *British Journal of Haematology*, **1992**, 80, 178-83	4.5	88
7	Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. *Leukemia*, **1992**, 6, 246-50	10.7	98
6	Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. *Leukemia*, **1992**, 6, 42-6	10.7	45
5	Therapy related myelodysplastic syndrome and leukemia with no "unfavourable" cytogenetic findings have a good response to intensive chemotherapy: a report on 15 cases. *Leukemia and Lymphoma*, **1991**, 5, 117-25	1.9	18
4	Prognostic value of dysmyelopoietic features in de novo acute myeloid leukaemia: a report on 132 patients. *International Journal of Laboratory Hematology*, **1990**, 12, 57-65		26
3	de novo myelodysplastic syndromes in adults aged 50 or less. A report on 37 cases. *Leukemia Research*, **1990**, 14, 1053-9	2.7	25
2	Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases. *British Journal of Haematology*, **1989**, 73, 61-7	4.5	174
1	Amplification of AML1 gene is present in childhood acute lymphoblastic leukemia but not in adult, and is not associated with AML1 gene mutation		1